Vaccinex, Inc.

Sutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c

Vaccinex, Inc. is on the hunt for a large partner to help bring pepinemab closer to market after it presented what it called positive Phase Ib/II data for the drug in Alzheimer’s disease. But given t

It was a great day for Alzheimer’s drug developers, regardless of the type of therapies in their pipelines, on 7 June when the US Food and Drug Administration granted accelerated approval for Biogen,

Roche Holding AG has abandoned its Phase III trial studying the investigational drug tominersen in Huntington's disease, ending hopes the antisense oligonucleotide could offer a game-changing therapy